| |
Mergers and acquisitions are common in clinical research, requiring flexibility and agility. When a sponsor changed mid-trial, Premier seamlessly maintained regulatory compliance, patient safety, and data integrity.
Learn how in our case study. 
|
|
Today’s Big NewsNov 8, 2024 |
| By Nick Paul Taylor Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to a 33% response rate but also three deaths in heavily pretreated cancer patients. |
|
|
|
By Nick Paul Taylor NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate. The biotech has decided to seek partners for its existing clinical candidate and other preclinical programs to free up cash for its new priority. |
By James Waldron Nkarta’s pivot from oncology to autoimmune disease has continued with the biotech halting work on its CD19-directed CAR NK in lymphoma to focus on lupus. |
Sponsored by Dell Technologies While artificial intelligence is on everyone’s minds and in many R&D plans, adoption of generative AI has been slow so far in life sciences. |
|
Create an optimal path to the clinic that best suits your molecule and critical milestones. We now offer a full suite of integrated drug substance/drug product DNA-to-IND programs to accelerate any molecule type to the clinic. Download our white papers to learn more about our tailored CMC strategies. 
|
|
By James Waldron AlloVir has been reeling after a trio of phase 3 trial failures last year led the company to shed almost all of its staff. Now, the immunotherapy biotech has found a new path forward by acquiring eye disease biotech Kalaris Therapeutics. |
By James Waldron Dynavax is giving up on its combination vaccine for tetanus, diphtheria and acellular pertussis (Tdap) after mulling phase 1 data for the shot. |
By Ayla Ellison,Gabrielle Masson,Andrea Park This week on "The Top Line," we take a closer look at this year’s biotech graveyard, which tracks biotechs that have closed or are winding down. |
By Darren Incorvaia,Zoey Becker Biopharma Trevena has whittled its team down to four people in efforts to cut costs, saying goodbye to several C-suite execs and continuing a strategic review that includes a possible asset sale, merger or closure of the company. |
By Darren Incorvaia California VC firm Aditum Bio is reaching across the Pacific to hatch a brand-new biotech. Teaming up with Leads Biolabs, a company based in China, the partners are launching Oblenio Bio to develop a tri-specific T-cell engager antibody for autoimmune diseases. |
By Darren Incorvaia The in vivo cell therapy seed that Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. The biotechs teamed up to develop a method to engineer immune cells called macrophages to target solid tumors. |
By Kevin Dunleavy Common oral medicines that have been used for decades as decongestants such as Sudafed, NyQuil and Benadryl may soon be cleared from shelves as the FDA has proposed to discontinue the sale of oral products containing the active ingredient phenylephrine. |
By Angus Liu AstraZeneca confirmed its China president has been detained by Chinese authorities. Pfizer plans to invest $1 billion in China in the next five years. Sun Pharma's JAK inhibitor Leqselvi was slapped with an injunction in a lawsuit with Incyte. And more. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we take a closer look at this year’s biotech graveyard, which tracks biotechs that have closed or are winding down. |
|
|---|
|
|
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
